—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...
Please provide your email address to receive an email when new articles are posted on . Gaps in access remain, though, as almost half of patients did not receive next-generation sequencing. “These ...
In this presentation the speaker will discuss latest developments in NSCLC precision therapy and biomarker landscape, and importance of NGS in NSCLC biomarker testing. He will review the NSCLC ...
Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer ...
In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into the following critical questions: We have now covered se ...
Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib We extracted real-world ...
Sarcopenia is emerging as a potential predictor of adverse outcomes for some solid tumors, but could this physical biomarker effectively stratify risk in patients with non-small cell lung cancer ...
Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402). This is an ASCO Meeting Abstract from ...
Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results